Replies to post #26943 on Biotech Values

[DewDiligence]

Re: Arixtra (fondaparinux) vs Lovenox (enoxaparin)

This is an excerpt from an editorial in the NEJM issue that published the head-to-head study (c/o SI, sorry no link):

>>
“Treatment of about 150 patients with fondaparinux rather than enoxaparin would result in three fewer bleeding events and one fewer death at 180 days. The noninferiority of fondaparinux with respect to the primary efficacy outcome and the superiority of fondaparinux with respect to major bleeding were also demonstrated in the subgroup of 7932 patients who underwent percutaneous coronary intervention. The specific anti–factor Xa activity of fondaparinux, as compared with the antithrombin and anti–factor Xa effect of enoxaparin, may in part be responsible for its safer profile. Fondaparinux inhibits factor Xa within the clot, preventing thrombus progression and thus enhancing effectiveness, but does not inhibit platelet function, thus enhancing safety.”
<<

There’s little question about which is the better drug.